IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Product Class Date Terms of Agreement
Starlix (nateglinide) A 1994 Licensed-in from Ajinomoto for marketing worldwide
(except Japan, South Korea, Taiwan, China, the UK, and
Ireland). In 1999, it acquired rights in the UK and Ireland.
In 2000, Merck KGaA acquired co-promotion and
co-marketing rights.
Sandimmun (ciclosporin) L 1993 Licensed-out to Allergan for topical ophthalmic uses
worldwide outside Japan and certain other Asian
countries.
Foradil (formoterol) R 1986 Licensed-in from Yamanouchi (now Astellas) by Ciba for
all markets outside Japan.
Xolair (omalizumab) R 1990 Novartis and Genentech share co-marketing rights in the
USA.
Lopresor/SR (metoprolol) C N/A Licensed-in from AstraZeneca for exclusive marketing in
the USA, and non-exclusive marketing in other countries.
Lotrel (amlodipine +
benazepril)
R&D Pipeline Products
C N/A Pfizer granted Novartis rights to use amlodipine in
combination with Novartis’ benazepril.
Product Class Date Terms of Agreement
IDX 899 J 2009 GlaxoSmithKline acquired exclusive global rights to
Idenix’s reverse transcriptase inhibitor IDX 899. Idenoix
is majority-owned by Novartis. All development of IDX
899 and associated costs will be assumed by GSK. Upon
successful commercialization, Idenix will receive double
digit, tiered royalties on worldwide sales.
elinogrel B 2009 Exclusive worldwide rights licensed-in from Portola
Pharmaceuticals. Novartis will have responsibility for
phase III trials, manufacturing and commercialization.
Portola has an option to co-promote elinogrel in the US in
the hospital and specialty markets and an option to
co-fund phase III trials and other development activities
in return for additional royalties.
© 2009 IMS Health In cor po rated or its af fil i ates Page 126